When Genome Maintenance Goes Badly Awry

Molecular Cell

Volumn 62, Issue 5, 2016, Pages 777-787

  Kass, Elizabeth M ^a   Moynahan, Mary Ellen ^a   Jasin, Maria ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Cancer genomes; Chromothripsis; Homologous recombination; Kataegis; Mutation signature

Indexed keywords

DNA; ANTINEOPLASTIC AGENT; TRANSCRIPTOME; TUMOR MARKER;

CANCER GENETICS; CANCER IMMUNOTHERAPY; DNA DAMAGE; DNA REPLICATION; DNA STRAND BREAKAGE; GENE MUTATION; GENOME; HOMOLOGOUS RECOMBINATION; HUMAN; NEOPLASM; NONHUMAN; REVIEW; SKIN TUMOR; ANIMAL; BIOSYNTHESIS; CELL TRANSFORMATION; CHEMISTRY; CHROMOSOME ABERRATION; CHROMOTHRIPSIS; DNA REPAIR; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; NEOPLASMS; PATHOLOGY; PHENOTYPE; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOTHRIPSIS; DNA; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME; HUMANS; MUTATION; NEOPLASMS; PHENOTYPE; TRANSCRIPTOME;

EID: 84971492722     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2016.05.021     Document Type: Review

References (114)

1. Abkevich V., Timms K.M., Hennessy B.T., Potter J., Carey M.S., Meyer L.A., Smith-McCune K., Broaddus R., Lu K.H., Chen J., et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 2012, 107:1776-1782.
2. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer ConsortiumICGC Breast Cancer Consortium, ICGC MMML-Seq ConsortiumICGC MMML-Seq Consortium, ICGC PedBrainICGC PedBrain.
3. Alexandrov L.B., Jones P.H., Wedge D.C., Sale J.E., Campbell P.J., Nik-Zainal S., Stratton M.R. Clock-like mutational processes in human somatic cells. Nat. Genet. 2015, 47:1402-1407.
4. Alexandrov L.B., Nik-Zainal S., Siu H.C., Leung S.Y., Stratton M.R. A mutational signature in gastric cancer suggests therapeutic strategies. Nat. Commun. 2015, 6:8683.
5. Alt F.W., Zhang Y., Meng F.L., Guo C., Schwer B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell 2013, 152:417-429.
6. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
7. Birkbak N.J., Wang Z.C., Kim J.Y., Eklund A.C., Li Q., Tian R., Bowman-Colin C., Li Y., Greene-Colozzi A., Iglehart J.D., et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012, 2:366-375.
8. Bouffet E., Larouche V., Campbell B.B., Merico D., de Borja R., Aronson M., Durno C., Krueger J., Cabric V., Ramaswamy V., et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 2016, Published online March 21, 2016. 10.1200/JCO.2016.66.6552.
9. Bouwman P., Aly A., Escandell J.M., Pieterse M., Bartkova J., van der Gulden H., Hiddingh S., Thanasoula M., Kulkarni A., Yang Q., et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 2010, 17:688-695.
10. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
11. Bunting S.F., Callén E., Wong N., Chen H.T., Polato F., Gunn A., Bothmer A., Feldhahn N., Fernandez-Capetillo O., Cao L., et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141:243-254.
12. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
13. The molecular taxonomy of primary prostate cancer. Cell 2015, 163:1011-1025. Cancer Genome Atlas Research Network.
14. Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73. Cancer Genome Atlas Research Network.
15. Casellas R., Basu U., Yewdell W.T., Chaudhuri J., Robbiani D.F., Di Noia J.M. Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity. Nat. Rev. Immunol. 2016, 16:164-176.
16. Ceccaldi R., Liu J.C., Amunugama R., Hajdu I., Primack B., Petalcorin M.I., O'Connor K.W., Konstantinopoulos P.A., Elledge S.J., Boulton S.J., et al. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature 2015, 518:258-262.
17. Chan K., Gordenin D.A. Clusters of multiple mutations: incidence and molecular mechanisms. Annu. Rev. Genet. 2015, 49:243-267.
18. Chapman J.R., Taylor M.R., Boulton S.J. Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell 2012, 47:497-510.
19. Chen X., Bahrami A., Pappo A., Easton J., Dalton J., Hedlund E., Ellison D., Shurtleff S., Wu G., Wei L., et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014, 7:104-112. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project.
20. Chen X., Pappo A., Dyer M.A. Pediatric solid tumor genomics and developmental pliancy. Oncogene 2015, 34:5207-5215.
21. Ciccia A., Elledge S.J. The DNA damage response: making it safe to play with knives. Mol. Cell 2010, 40:179-204.
22. Cole F., Keeney S., Jasin M. Evolutionary conservation of meiotic DSB proteins: more than just Spo11. Genes Dev. 2010, 24:1201-1207.
23. Crasta K., Ganem N.J., Dagher R., Lantermann A.B., Ivanova E.V., Pan Y., Nezi L., Protopopov A., Chowdhury D., Pellman D. DNA breaks and chromosome pulverization from errors in mitosis. Nature 2012, 482:53-58.
24. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
25. Genovese G., Kähler A.K., Handsaker R.E., Lindberg J., Rose S.A., Bakhoum S.F., Chambert K., Mick E., Neale B.M., Fromer M., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 2014, 371:2477-2487.
26. Ghezraoui H., Piganeau M., Renouf B., Renaud J.B., Sallmyr A., Ruis B., Oh S., Tomkinson A.E., Hendrickson E.A., Giovannangeli C., et al. Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining. Mol. Cell 2014, 55:829-842.
27. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., Isaacs W.B., Bova G.S., Liu W., Xu J., et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 2010, 42:668-675.
28. Haradhvala N.J., Polak P., Stojanov P., Covington K.R., Shinbrot E., Hess J.M., Rheinbay E., Kim J., Maruvka Y.E., Braunstein L.Z., et al. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell 2016, 164:538-549.
29. Hartung M.L., Gruber D.C., Koch K.N., Grüter L., Rehrauer H., Tegtmeyer N., Backert S., Müller A. H. pylori-Induced DNA Strand Breaks Are Introduced by Nucleotide Excision Repair Endonucleases and Promote NF-κB Target Gene Expression. Cell Rep. 2015, 13:70-79.
30. Hashimoto Y., Ray Chaudhuri A., Lopes M., Costanzo V. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat. Struct. Mol. Biol. 2010, 17:1305-1311.
31. Hatch E.M., Fischer A.H., Deerinck T.J., Hetzer M.W. Catastrophic nuclear envelope collapse in cancer cell micronuclei. Cell 2013, 154:47-60.
32. Henderson S., Chakravarthy A., Su X., Boshoff C., Fenton T.R. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 2014, 7:1833-1841.
33. Hoopes J.I., Cortez L.M., Mertz T.M., Malc E.P., Mieczkowski P.A., Roberts S.A. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. Cell Rep. 2016, 14:1273-1282.
34. Hugo W., Zaretsky J.M., Sun L., Song C., Moreno B.H., Hu-Lieskovan S., Berent-Maoz B., Pang J., Chmielowski B., Cherry G., et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 2016, 165:35-44.
35. Jaiswal S., Fontanillas P., Flannick J., Manning A., Grauman P.V., Mar B.G., Lindsley R.C., Mermel C.H., Burtt N., Chavez A., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 2014, 371:2488-2498.
36. Jasin M., Rothstein R. Repair of strand breaks by homologous recombination. Cold Spring Harb. Perspect. Biol. 2013, 5:a012740.
37. Jensen R.B., Carreira A., Kowalczykowski S.C. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 2010, 467:678-683.
38. Jhuraney A., Velkova A., Johnson R.C., Kessing B., Carvalho R.S., Whiley P., Spurdle A.B., Vreeswijk M.P., Caputo S.M., Millot G.A., et al. BRCA1 Circos: a visualisation resource for functional analysis of missense variants. J. Med. Genet. 2015, 52:224-230. Evidence-based Network for the Interpretation of Germline Mutant Alleles Consortium.
39. Jones S., Chen W.D., Parmigiani G., Diehl F., Beerenwinkel N., Antal T., Traulsen A., Nowak M.A., Siegel C., Velculescu V.E., et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. USA 2008, 105:4283-4288.
40. Kazanov M.D., Roberts S.A., Polak P., Stamatoyannopoulos J., Klimczak L.J., Gordenin D.A., Sunyaev S.R. APOBEC-induced cancer mutations are uniquely enriched in early-replicating, gene-dense, and active chromatin regions. Cell Rep. 2015, 13:1103-1109.
41. Kim J., Mouw K.W., Polak P., Braunstein L.Z., Kamburov A., Tiao G., Kwiatkowski D.J., Rosenberg J.E., Van Allen E.M., D'Andrea A.D., Getz G. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 2016, Published online April 25, 2015. 10.1038/ng.3557.
42. Kloosterman W.P., Tavakoli-Yaraki M., van Roosmalen M.J., van Binsbergen E., Renkens I., Duran K., Ballarati L., Vergult S., Giardino D., Hansson K., et al. Constitutional chromothripsis rearrangements involve clustered double-stranded DNA breaks and nonhomologous repair mechanisms. Cell Rep. 2012, 1:648-655.
43. Kloosterman W.P., Koster J., Molenaar J.J. Prevalence and clinical implications of chromothripsis in cancer genomes. Curr. Opin. Oncol. 2014, 26:64-72.
44. Korbel J.O., Campbell P.J. Criteria for inference of chromothripsis in cancer genomes. Cell 2013, 152:1226-1236.
45. Kovtun I.V., Murphy S.J., Johnson S.H., Cheville J.C., Vasmatzis G. Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer. Oncotarget 2015, 6:29087-29096.
46. Langevin F., Crossan G.P., Rosado I.V., Arends M.J., Patel K.J. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011, 475:53-58.
47. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
48. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015, 372:2509-2520.
49. Leibowitz M.L., Zhang C.Z., Pellman D. Chromothripsis: a new mechanism for rapid karyotype evolution. Annu. Rev. Genet. 2015, 49:183-211.
50. Lin C., Yang L., Tanasa B., Hutt K., Ju B.G., Ohgi K., Zhang J., Rose D.W., Fu X.D., Glass C.K., Rosenfeld M.G. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 139:1069-1083.
51. Lyu Y.L., Lin C.P., Azarova A.M., Cai L., Wang J.C., Liu L.F. Role of topoisomerase IIbeta in the expression of developmentally regulated genes. Mol. Cell. Biol. 2006, 26:7929-7941.
52. Maciejowski J., Li Y., Bosco N., Campbell P.J., de Lange T. Chromothripsis and kataegis induced by telomere crisis. Cell 2015, 163:1641-1654.
53. Madabhushi R., Gao F., Pfenning A.R., Pan L., Yamakawa S., Seo J., Rueda R., Phan T.X., Yamakawa H., Pao P.C., et al. Activity-induced dna breaks govern the expression of neuronal early-response genes. Cell 2015, 161:1592-1605.
54. Malhotra A., Lindberg M., Faust G.G., Leibowitz M.L., Clark R.A., Layer R.M., Quinlan A.R., Hall I.M. Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms. Genome Res. 2013, 23:762-776.
55. Martincorena I., Roshan A., Gerstung M., Ellis P., Van Loo P., McLaren S., Wedge D.C., Fullam A., Alexandrov L.B., Tubio J.M., et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 2015, 348:880-886.
56. Mateo J., Carreira S., Sandhu S., Miranda S., Mossop H., Perez-Lopez R., Nava Rodrigues D., Robinson D., Omlin A., Tunariu N., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 2015, 373:1697-1708.
57. Mateos-Gomez P.A., Gong F., Nair N., Miller K.M., Lazzerini-Denchi E., Sfeir A. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. Nature 2015, 518:254-257.
58. McEvoy J., Nagahawatte P., Finkelstein D., Richards-Yutz J., Valentine M., Ma J., Mullighan C., Song G., Chen X., Wilson M., et al. RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget 2014, 5:438-450.
59. McGranahan N., Favero F., de Bruin E.C., Birkbak N.J., Szallasi Z., Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 2015, 7:283ra54.
60. Meyer S., Tischkowitz M., Chandler K., Gillespie A., Birch J.M., Evans D.G. Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling. J. Med. Genet. 2014, 51:71-75.
61. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
62. Molenaar J.J., Koster J., Zwijnenburg D.A., van Sluis P., Valentijn L.J., van der Ploeg I., Hamdi M., van Nes J., Westerman B.A., van Arkel J., et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012, 483:589-593.
63. Morganella S., Alexandrov L.B., Glodzik D., Zou X., Davies H., Staaf J., Sieuwerts A.M., Brinkman A.B., Martin S., Ramakrishna M., et al. The topography of mutational processes in breast cancer genomes. Nat. Commun. 2016, 7:11383.
64. Morrison C.D., Liu P., Woloszynska-Read A., Zhang J., Luo W., Qin M., Bshara W., Conroy J.M., Sabatini L., Vedell P., et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc. Natl. Acad. Sci. USA 2014, 111:E672-E681.
65. Moynahan M.E. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene 2002, 21:8994-9007.
66. Moynahan M.E., Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat. Rev. Mol. Cell Biol. 2010, 11:196-207.
67. Moynahan M.E., Chiu J.W., Koller B.H., Jasin M. Brca1 controls homology-directed DNA repair. Mol. Cell 1999, 4:511-518.
68. Moynahan M.E., Pierce A.J., Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 2001, 7:263-272.
69. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Van Loo P., Greenman C.D., Raine K., Jones D., Hinton J., Marshall J., Stebbings L.A., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993. Breast Cancer Working Group of the International Cancer Genome Consortium.
70. Nik-Zainal S., Davies H., Staaf J., Ramakrishna M., Glodzik D., Zou X., Martincorena I., Alexandrov L.B., Martin S., Wedge D.C., et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 2016, 10.1038/nature17676.
71. Norquist B.M., Harrell M.I., Brady M.F., Walsh T., Lee M.K., Gulsuner S., Bernards S.S., Casadei S., Yi Q., Burger R.A., et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016, 2:482-490.
72. Nougayrède J.P., Homburg S., Taieb F., Boury M., Brzuszkiewicz E., Gottschalk G., Buchrieser C., Hacker J., Dobrindt U., Oswald E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006, 313:848-851.
73. Orthwein A., Noordermeer S.M., Wilson M.D., Landry S., Enchev R.I., Sherker A., Munro M., Pinder J., Salsman J., Dellaire G., et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature 2015, 528:422-426.
74. Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., Kemp Z., Spain S.L., Guarino E., Salguero I., et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 2013, 45:136-144. CORGI Consortium, WGS500 ConsortiumWGS500 Consortium.
75. Patch A.M., Christie E.L., Etemadmoghadam D., Garsed D.W., George J., Fereday S., Nones K., Cowin P., Alsop K., Bailey P.J., et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015, 521:489-494. Australian Ovarian Cancer Study Group.
76. Pennington K.P., Walsh T., Harrell M.I., Lee M.K., Pennil C.C., Rendi M.H., Thornton A., Norquist B.M., Casadei S., Nord A.S., et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 2014, 20:764-775.
77. Pleasance E.D., Cheetham R.K., Stephens P.J., McBride D.J., Humphray S.J., Greenman C.D., Varela I., Lin M.L., Ordóñez G.R., Bignell G.R., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
78. Pontel L.B., Rosado I.V., Burgos-Barragan G., Garaycoechea J.I., Yu R., Arends M.J., Chandrasekaran G., Broecker V., Wei W., Liu L., et al. Endogenous formaldehyde is a hematopoietic stem cell genotoxin and metabolic carcinogen. Mol. Cell 2015, 60:177-188.
79. Popova T., Manié E., Rieunier G., Caux-Moncoutier V., Tirapo C., Dubois T., Delattre O., Sigal-Zafrani B., Bollet M., Longy M., et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012, 72:5454-5462.
80. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 2015, 33:1974-1982.
81. Prakash R., Zhang Y., Feng W., Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol. 2015, 7:a016600.
82. Rausch T., Jones D.T., Zapatka M., Stütz A.M., Zichner T., Weischenfeldt J., Jäger N., Remke M., Shih D., Northcott P.A., et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012, 148:59-71.
83. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
84. Roberts S.A., Gordenin D.A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 2014, 14:786-800.
85. Roberts S.A., Sterling J., Thompson C., Harris S., Mav D., Shah R., Klimczak L.J., Kryukov G.V., Malc E., Mieczkowski P.A., et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol. Cell 2012, 46:424-435.
86. Roberts S.A., Lawrence M.S., Klimczak L.J., Grimm S.A., Fargo D., Stojanov P., Kiezun A., Kryukov G.V., Carter S.L., Saksena G., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013, 45:970-976.
87. Robinson D., Van Allen E.M., Wu Y.M., Schultz N., Lonigro R.J., Mosquera J.M., Montgomery B., Taplin M.E., Pritchard C.C., Attard G., et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015, 161:1215-1228.
88. Roy R., Chun J., Powell S.N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 2011, 12:68-78.
89. Schlacher K., Christ N., Siaud N., Egashira A., Wu H., Jasin M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 2011, 145:529-542.
90. Schlacher K., Wu H., Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 2012, 22:106-116.
91. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
92. Seplyarskiy V.B., Soldatov R.A., Popadin K.Y., Antonarakis S.E., Bazykin G.A., Nikolaev S.I. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. Genome Res. 2016, 26:174-182.
93. Seshagiri S. The burden of faulty proofreading in colon cancer. Nat. Genet. 2013, 45:121-122.
94. Sfeir A., Symington L.S. Microhomology-mediated end joining: a back-up survival mechanism or dedicated pathway?. Trends Biochem. Sci. 2015, 40:701-714.
95. Shlien A., Campbell B.B., de Borja R., Alexandrov L.B., Merico D., Wedge D., Van Loo P., Tarpey P.S., Coupland P., Behjati S., et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 2015, 47:257-262. Biallelic Mismatch Repair Deficiency Consortium.
96. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371:2189-2199.
97. Stark J.M., Pierce A.J., Oh J., Pastink A., Jasin M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol. Cell. Biol. 2004, 24:9305-9316.
98. Stephens P.J., Greenman C.D., Fu B., Yang F., Bignell G.R., Mudie L.J., Pleasance E.D., Lau K.W., Beare D., Stebbings L.A., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
99. Strickland K.C., Howitt B.E., Shukla S.A., Rodig S., Ritterhouse L.L., Liu J.F., Garber J.E., Chowdhury D., Wu C.J., D'Andrea A.D., et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016, 10.18632/oncotarget.7277.
100. Telli M.L., Timms K.M., Reid J.E., Hennessy B., Mills G.B., Jensen K.C., Szallasi Z., Barry W.T., Winer E.P., Tung N., et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple negative breast cancer. Clin. Cancer Res. 2016, clincanres.2477.2015.
101. Toller I.M., Neelsen K.J., Steger M., Hartung M.L., Hottiger M.O., Stucki M., Kalali B., Gerhard M., Sartori A.A., Lopes M., Müller A. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc. Natl. Acad. Sci. USA 2011, 108:14944-14949.
102. Van Allen E.M., Miao D., Schilling B., Shukla S.A., Blank C., Zimmer L., Sucker A., Hillen U., Geukes Foppen M.H., Goldinger S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015, 350:207-211.
103. Vieira V.C., Leonard B., White E.A., Starrett G.J., Temiz N.A., Lorenz L.D., Lee D., Soares M.A., Lambert P.F., Howley P.M., Harris R.S. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 2014, 5:5.
104. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
105. Waddell N., Pajic M., Patch A.M., Chang D.K., Kassahn K.S., Bailey P., Johns A.L., Miller D., Nones K., Quek K., et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518:495-501. Australian Pancreatic Cancer Genome Initiative.
106. Weckselblatt B., Hermetz K.E., Rudd M.K. Unbalanced translocations arise from diverse mutational mechanisms including chromothripsis. Genome Res. 2015, 25:937-947.
107. Wei P.C., Chang A.N., Kao J., Du Z., Meyers R.M., Alt F.W., Schwer B. Long neural genes harbor recurrent dna break clusters in neural stem/progenitor cells. Cell 2016, 164:644-655.
108. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
109. Xia B., Sheng Q., Nakanishi K., Ohashi A., Wu J., Christ N., Liu X., Jasin M., Couch F.J., Livingston D.M. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 2006, 22:719-729.
110. Yates L.R., Gerstung M., Knappskog S., Desmedt C., Gundem G., Van Loo P., Aas T., Alexandrov L.B., Larsimont D., Davies H., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 2015, 21:751-759.
111. Zhang Y., Jasin M. An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway. Nat. Struct. Mol. Biol. 2011, 18:80-84.
112. Zhang C.Z., Spektor A., Cornils H., Francis J.M., Jackson E.K., Liu S., Meyerson M., Pellman D. Chromothripsis from DNA damage in micronuclei. Nature 2015, 522:179-184.
113. Zimmer J., Tacconi E.M., Folio C., Badie S., Porru M., Klare K., Tumiati M., Markkanen E., Halder S., Ryan A., et al. Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds. Mol. Cell 2016, 61:449-460.
114. Zimmermann M., de Lange T. 53BP1: pro choice in DNA repair. Trends Cell Biol. 2014, 24:108-117.